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Abstract
Breast cancer (BrCa) remains the leading cause of cancer-related deaths in women
worldwide (2). Current research suggests that the transcription factor RUNX1 functions as a
regulator and potentially as a tumor suppressor in breast cancer progression (4). RUNX1 is the
most dominant RUNX family member expressed in normal mammary epithelial cells (10) and it
has been demonstrated that RUNX1 activity decreases as breast cancer aggression increases.
Yet, the mechanism of this regulation remains unclear. The significance of this project is to
further the in-depth investigation of the relationship between RUNX1 and differentially
expressed genes that influence human breast cancer progression. This study addresses the
hypothesis that RUNX1 controls a myriad of genes that play roles in the suppression of the
breast cancer stem cell (BCSC) population, a subpopulation of cancer cells that are capable of
self-renewal and demonstrate an ability to resist common chemotherapies and treatments.
BCSCs are therefore the most dangerous and most essential to eradicate if the cancer is to be
cured (11). To test this hypothesis, RUNX1 was downregulated in the MCF10A breast cancer cell
line using both the inducible CRISPRi and the shRNA-mediated gene knockdown approaches.
Fluorescence-activated cell sorting (FACS) and quantitative polymerase chain reaction (qPCR)
confirmed successful knockdown of RUNX1 and further genetic and proteomic expression
analyses of known breast cancer driver genes was performed to determine how RUNX1
depletion exerts control over the progression of BrCa. It was found that RUNX1 may aid in
maintaining the epithelial phenotype in BrCa while also suppressing the expression of key BrCa
driver genes such as phosphatidylinositol-3-kinases (PI3K) PIK3CA and PIK3R1. Investigating the
role of RUNX1 as a suppressor of the BCSC population adds a new level of knowledge to the
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field of breast cancer research, and may allow development of a safer, more targeted, and
more effective plan of action to eradicate one of the deadliest diseases that exists today.
Introduction
Cancer is an incredibly complex and diverse disease that has the potential to affect
every cell, tissue and organ of the body. Cancers touch every area of the globe and do not
distinguish among age, sex, race, or ethnicity. Yet, underlying all cancers are key cellular and
molecular hallmarks that allow cancers to evolve into lethal neoplastic diseases we see every
day, from acute myeloid leukemia to breast cancer.
For decades, the cellular and molecular foundation of cancer cells has been explained as
six hallmarks that contribute to the canonical cancer cell: a cell that displays an ability to rapidly
grow, proliferate and divide, eventually becoming immortal and capable of invasion and
metastasis. By sustaining proliferative signaling via an array of tyrosine kinase domains,
paracrine or autocrine signaling, the cancer cell exhibits chronic proliferation that is largely out
of control (5). This fundamental property of the cancer cell is further compounded by its ability
to evade the regulatory suppression of growth. Contact inhibition is abolished and a net loss of
the canonical growth suppressors that include retinoblastoma-associated protein (RB1) and
TP53, a well-documented protein with anticancer activity via DNA damage response and cell
cycle control, is often seen. In parallel to the cancer cell evading suppression of growth, the
ability to resist cell death is also a characteristic of cancers. In a healthy cell, hyperproliferation
often leads to increased DNA damage, which is sensed by the cell to either fix the DNA damage
or induce apoptosis if the damage is too severe to be repaired. As these DNA damage sensors
are lost, the apoptotic cascade fails, allowing the DNA damaged cell to continue
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hyperproliferation (5). As these events transpire, the cell may soon reach a state of
immortalization, in which repetitive divisions and growth do not result in cell senescence or
crisis.
In order for a cancer cell to sustain the proliferative state, nutrient and energy
requirements must still be met. The cell requires oxygen, nutrients, and an outlet for waste
products such as carbon dioxide. As the cancer cell continues to mutate and progress, the
angiogenic switch, often seen in embryonic and prenatal development, is turned on via hypoxia
and oncogene signaling (5). This supports neoplastic growth by continually sprouting new blood
vessels for nutrient delivery and waste removal. In the most progressive state, the cancer will
activate mechanisms that allow for invasion and metastasis. It is thought that the loss of cell to
cell and cell to extracellular matrix adhesion molecules allows the cancer to spread throughout
the body. It is at this stage where the epithelial to mesenchymal transition (EMT) has been
observed, a regulatory pathway that allows the cell to invade, metastasize, and resist the
normal apoptotic programs. Key transcriptional factors are at play during EMT, most notably
Snail, Slug, Twist, and Zeb1/2, all of which function to cause a net loss in cellular E-cadherin, a
key cellular adhesion molecule (12). This marks the process known as the invasion-metastasis
cascade. Following local invasion, intravasation occurs allowing the cell to travel throughout the
circulatory and lymphatic systems. The cell then leaves this mode of transit via extravasation to
settle in a distant part of the body, ideally one that provides a rich microenvironment for the
cell to colonize the area and eventually grow into a macroscopic tumor. Most often, this
cascade results in the cancer cell colonizing a niche environment, an area of the body that is
rich in nutrients necessary for cellular survival. As these events transpire in a successive
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manner, the result is an invasive subpopulation of cancer that can be aggressive and often
lethal.
In just the last decade, tumors have been categorized as functioning and complex organs.
No longer can a tumor be simply considered a collection of homogenous cells. Rather, a tumor is
made up of a diverse array of heterogeneous cells, each type specialized in its own way and
harboring unique mutations (5). These types may include, but are not limited to, local stem and
progenitor cells, immune inflammatory cells, cancer cells, pericytes, endothelial cells, cancerassociated fibroblasts, invasive cancer cells, and cancer stem cells (CSCs) (11). Each of these cell
types performs a unique function within the tumor organ and the tumor microenvironment.
Immune inflammatory cells, for example, demonstrate tumor-promoting as well as tumorsuppressive subtypes (Figure 1).
Figure 1: The Heterogenous Cells
of the Tumor Microenvironment.
A multitude of cell types constitute
solid tumors that together enable
tumor growth and progression
(upper). The characteristics of the
cells evolve as they progress from
a primary tumor, to an invasive or
metastatic state (lower) (5).

Acquired from Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011
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Recently, CSCs have come to the forefront of cancer research, as these cells are able to
propagate new tumors upon host inoculation. Additionally, CSCs characteristically display
expression of markers that are also found on stem cells in the same tissue-of-origin. Similar to
healthy stem cells, CSCs are capable of self-renewal and therefore pose a significant threat
when coupled with the canonical trademarks of a cancer cell (11). One such threat is an
increased resistance to some of the most widely used cancer therapies today, such as
chemotherapy. Furthermore, when a subpopulation of the tumor is resistant to
chemotherapeutics, the treatment behaves as a selective pressure on the cancer population,
allowing only the resistant CSCs to survive and foster a stronger and potentially deadly patient
relapse. Investigating CSCs is therefore critical to understand how cancer progresses and to
develop cancer therapies that truly eradicate the genetically heterogeneous tumor.
In mammals, three RUNX genes encode transcription factors that serve as master
regulators of development. RUNX1, RUNX2, and RUNX3 each display unique expression
patterns that are critical to certain tissues and organ systems (4). RUNX proteins operate as
effectors of crucial developmental pathways, including transforming growth factor-b (TGF-b),
WNT, Notch, and receptor tyrosine kinases (4). This has led the RUNX family to be an important
area of interest in oncological and carcinogenesis research. RUNX1 is essential for normal
hematopoiesis and is heavily involved in human leukemia, while RUNX2 is an important bone
lineage factor involved in osteosarcoma. In metastatic breast and prostate cancers, RUNX2 is
often overexpressed, pointing to a role in tumorigenesis and metastasis (4).
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Figure 2: Functional domains of RUNX proteins and their interacting proteins. RUNX proteins
contain a highly conserved Runt domain at the N-terminus at which CBF𝛃 and DNA bind. The
Runt domains exhibit 90% homology among all RUNX family members (8).
The RUNX1 gene is located on the long arm of chromosome 21 (21q22.12) and
expression of RUNX1 is regulated by two promoters known as P1 (distal) and P2 (proximal) (8).
Due to alternative splicing, the RUNX1 gene is capable of producing several isoforms that
encode proteins with unique properties. Each RUNX family member contains a highly conserved
DNA-binding domain known as the Runt domain (Figure 2). It is in this domain that the
heterodimeric binding partner, core-binding factor-beta (CBFb), binds and displaces the
inhibitory domain of RUNX. CBFb is therefore crucial to gene regulation of the developmental
pathways of hematopoiesis and osteogenesis (13). Though CBFb does not directly bind DNA, it
exerts control by allosterically enhancing DNA binding at certain enhancers and gene promoters
(13). The Runt domain is also subject to frequent mutations which result in an overall loss in
DNA-binding ability. Furthermore, the RUNX proteins are subject to post-translation
modifications, allowing the transcription factors to fulfill their role as master regulators of
development. These modifications include methylation, acetylation, phosphorylation and
ubiquitylation, all of which facilitate the impressive list of activating and inhibitory
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developmental control mechanisms exerted by RUNX1 (4). RUNX1 also associates with cyclindependent kinases (CDKs), and its phosphorylation status determines the stability of the
protein and the control of the cell transition from G1 to S phase and further proliferation (4).
Due to the master regulator role of RUNX1 in developmental control, genomic
dysregulation can lead to the onset of many types of cancer, especially those derived from
hematopoietic cells. Similarly, RUNX1 aberrations resulting from specific chromosomal
translocations and gene fusions lead to the onset of specific leukemia subtypes, such as the
development of acute lymphoblastic leukemia (ALL) following t(12;21) and the resulting TELAML1 fusion gene (4).
As stated, the role of RUNX1 in hematopoiesis is well-known, but its function in
epithelial cells is much less understood. RUNX proteins recognize a core genomic sequence (4)
and recruit mediators of signaling pathways, chromatin remodelers, and chromatin organizing
proteins to regulatory regions of target genes. These genes in turn coordinate the control of
proliferation, growth and differentiation (8, 14, 15). Several reports have demonstrated a lower
expression of RUNX1 across BrCa progression (3, 16, 17); RUNX1 expression decreases as the
aggression of the breast cancer increases (4). Therefore, in breast cancer specifically, increased
RUNX1 expression is a characteristic of good prognosis, indicating that RUNX1 acts as a tumor
suppressor (3). RUNX factors are implicated in normal mammary stem cell maintenance (18-21)
and mammary gland development (22-25). Additionally, both RUNX1 and its heterodimeric
binding partner CBFb are prevalent among predicted driver mutations in BrCa (2, 26, 27). The
majority of these mutations indicate a loss of function (28). Knockdown of RUNX1 facilitates
estrogen-induced Wnt signaling (10), an epithelial to mesenchymal transition (3) and
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morphological defects (29). Furthermore, RUNX1 contributes to p53-dependent DNA damage
response, a key mechanism facilitated by the p53 tumor suppressor (3). There are conflicting
reports whether RUNX1 acts as a tumor suppressor or an oncogene in BrCa; one explanation for
this discrepancy may be due to the model that BrCa consists of a diverse group of subtypes
(30). These BrCa subtypes have different cellular origins (luminal versus basal) and molecular
alterations (e.g., hormonal status including ER, PR, and HER2) that result in malignancy. More
work is required to determine the molecular mechanisms by which RUNX1 functions in BrCa.
Our research group has demonstrated that RUNX1 is involved in a key biological
process, the epithelial to mesenchymal transition (EMT) (3). During EMT, epithelial cadherin (Ecadherin/CDH1) and tight cell-cell junctions are lost, allowing epithelial cells to transition to
mesenchymal cells (31). Normally, EMT is a process crucial to development, most notably
gastrulation and organ development during embryogenesis (12). However, EMT is also utilized
by early stage tumors to form invasive malignancies in breast cancer (12). As a result of EMT,
breast cancers display invasive properties that allow the cancer to metastasize and progress to
a more aggressive state with a poorer prognosis. During progression, early stage cancer cells
displaying the epithelial phenotype, a state that requires cell to cell contact and lacking
mobility, transition to a mesenchymal phenotype. Mesenchymal cells lack a polarized
cytoskeleton and therefore display a change in cellular morphology that is more spindleshaped, aiding in the cell’s ability to metastasize and survive with reduced cell to cell contact
(Figure 3) (3).
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Figure 3: The Epithelial to Mesenchymal Transition contributes to the progression of cancer.
As EMT progresses, cells lack cellular adhesion markers such as E-cadherin and express
mesenchymal markers vimentin and N-cadherin. The mesenchymal phenotype contributes to
cellular invasion and cancer metastasis (6).

Recent research demonstrates that RUNX1 maintains the normal epithelial phenotype
and that RUNX1 expression is inversely related to the relative aggression of breast cancer (3).
For instance, in the MCF10 breast cancer cell line progression series, RUNX1 RNA expression
decreases as the cancer aggression progresses from normal-like MCF10A mammary epithelial
cells through tumorigenic MCF10AT1 cells to the metastatic MCF10CA1a cells (Figure 4A) (3).
Furthermore, by quantitatively analyzing expression of the cellular markers E-cadherin and
vimentin through the MCF10 series, EMT has been shown to progress as RUNX1 expression
decreases (Figure 4B). This is exemplified by a decrease of E-cadherin expression and an
increase in expression of vimentin, an intermediate filament present in mesenchymal cells. This
relationship between RUNX1 and EMT further supports the role of RUNX1 as a tumor
suppressor in breast cancer.
Moreover, upon shRNA-mediated knockdown of RUNX1 in MCF10A cells, E-cadherin
exhibits a significant decrease in mRNA expression while both vimentin and N-cadherin, a
known protein marker for cancer metastasis, display a significant increase in mRNA expression
(Figure 5) (3).
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4A

4B
RUNX1

Figure 4: Expression profiles in the MCF10A Breast Cancer Cell Series. A: RUNX1 RNA
expression by RT-qPCR of normal mammary-like MCF10A cells, MCF10A-derived
tumorigenic MCF10AT1 cells, and metastatic MCF10CA1a cells demonstrates a reduction
in RUNX1 as the series progresses. B: Protein expression by western blot analysis of the
MCF10A series demonstrates a reduction in RUNX1 and E-cadherin and an increase in
Vimentin as the series progresses to metastasis (3).
5A

5C

RUNX1 mRNA

N-cadherin mRNA

5B

E-cadherin mRNA

5D

Vimentin mRNA

Figure 5: RUNX1 Depletion in MCF10A Cells Advances the Mesenchymal-like Phenotype.
Western blot analyses of cell lysates show a decrease in RUNX1 expression (A) upon shRNAmediated knockdown of RUNX1 relative to the non-silencing (NS) shRNA construct. A
decrease in E-cadherin (B) is observed upon RUNX1 knockdown as well as an increase in
the mesenchymal genes N-cadherin (C) and Vimentin (D) (3).

11

Recent studies have shown that overexpression of RUNX1 is able to rescue and reverse
the EMT phenotype after TGFb-induced EMT. Upon overexpression of RUNX1, E-cadherin
mRNA expression increased while vimentin mRNA expression decreased. This rescue study
therefore established the significant role of RUNX1 in preventing EMT (3). With the evidence of
EMT progression as a result of RUNX1 knockdown, RUNX1 can be considered a tumor
suppressor gene in mammary epithelial cells.
In all cancers, genomic mutations may be classified as driver or passenger mutations. A
driver mutation is one that promotes the progression of the cancer and is causally implicated in
doing so. Driver mutations confer growth advantages on the cancer and are therefore positively
selected for in the tumor microenvironment. Conversely, mutations known as passenger
mutations are not selected for, as they do not directly contribute to cancer development.
Passenger mutations commonly occur during cellular division and do not carry severe
functional consequences. Therefore, the more developed cancer will harbor a number of driver
mutations along with a variety of passenger mutations that were carried throughout the
development of the cancer (36). In 2016, Serena Nik-Zainal and colleagues analyzed whole
genome sequences of 560 patient-derived breast cancers using massively-parallel sequencing
to gain a better understanding of the genetic mutations driving BrCa, clonal advantages, and
the processes generating these somatic mutations (1). Together with transcriptome
sequencing, microRNA expression and DNA methylation data, as well as data from other studies
(32-35), the authors analyzed information from a total of 1,332 breast cancers. Utilizing a list of
727 known human cancer genes (not specific to BrCa), this study found the 10 most frequently
mutated genes in these 1,332 BrCa cases: TP53, PIK3CA, MYC, CCND1, PTEN, ERBB2, GATA3,
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RB1, MAP3K1, and chr8:ZNF703/FGFR1 (1). These 10 common BrCa mutations accounted for
62% of the total 194 driver mutations found.
Modern day technologies that disrupt gene expression of a specific target serve as very
powerful analytical tools in scientific research. One such tool developed in recent years is
known as CRISPRi (clustered regularly interspaced short palindromic repeat interference). The
system was discovered in bacteria, when three groups noticed that some CRISPR spacers were
identical to sequences of viruses (37). A deeper look into the CRISPR array found that CRISPRCas (CRISPR associated proteins) systems are responsible for adaptive immunity in bacteria,
with the ability to acquire fragments of foreign DNA and incorporate them into the genome to
allow for sequence-specific resistance and degradation if that foreign DNA target were to
invade the cell again (37). The CRISPR-Cas system has come to the forefront of research
investigations interested in gene function, developmental pathways, and mechanisms of
disease. In this project, inducible CRISPRi-dCas9-KRAB was utilized to specifically repress and
knockdown the expression of RUNX1 in the MCF10A breast cancer cell series.
Another modern day technology critical to loss-of-function studies and gene depletion
analyses is known as RNA interference (RNAi). The mechanism at work in RNAi is based on the
sequence-specific degradation or translation interference of mRNA through the cytoplasmic
delivery of double-stranded RNA that carries the identical sequence to the target gene (38).
Target-specific degradation is achieved by use of the cell’s endogenous RNA-induced silencing
complex, commonly known as RISC, as well as the endogenous enzyme known as Dicer. Gene
silencing is also achieved by siRNA binding the target mRNA to physically interfere with the
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cell’s translation machinery (39). In this project, shRNA was successfully utilized to knockdown
the expression of RUNX1 in the MCF10 breast cancer cell series at the transcriptome level.
Future directions for this project include investigating the mechanism by which RUNX1
suppresses tumor progression. In response to RUNX1 knockdown, this project will analyze the
downstream effects of genes known to be activated or suppressed as cancer progresses,
commonly known as cancer driver genes. Through identification of potential BrCa driver genes
regulated by RUNX1, further studies may investigate the role these genes have in the BCSC
population; contributing important evidence for potential targets for modern, safe, and
efficient BrCa therapies.
Methods
Tissue Culture
The MCF10A (10A) cell progression model was used for all experiments in this study.
The MCF10 breast cancer cell progression series is derived from benign breast tissue from a
woman with fibrocystic breasts. The MCF10A cells are immortalized, normal-like and nonmalignant, attached epithelial cells, while the MCF10AT1 (AT1) cells are derived from MCF10A
cells transformed with constitutively activated H-RAS, resulting in premalignant cells capable of
neoplasm progression. The MCF10CA1a (CA1a) cells are the final cells in the progression, which
are fully malignant, readily forming large tumors and capable of metastasizing. All three cell
lines were produced from the same patient and thus have a similar genetic background.
The media used for both 10A and AT1 cells consisted of DMEM/F12 (HycloneSH30271.02) and 5% horse serum (Gibco 16050 lot #1075876) and 10ug/ml of human insulin
(Sigma I-1882) and 20ng/ml of human epidermal growth factor and 100ng/ml of cholera toxin
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(Sigma C-8052) and 0.5 ug/ml of Hydrocortisone (Sigma H-0888) and Pen/Strep, and LGlutamine.
Cells were cultured in growth media, which was replaced every 24-48 hours by
removing the old media and replacing with the new media warmed to 37°C. For a 100mm petri
dish, 10mL of media was used. As the culture reached 75-80% confluency, the cells were
passaged using a splitting ratio of approximately 1:10. The cells were passaged every 2-4 days
as the cell density approached approximately 7-10 x 106 cells per 100mm dish. The seeding
density for plating cells was approximately 1-2 x 106 cells per 100mm dish. All cell cultures were
maintained at 37°C.
CRISPRi Oligo Design and Cloning
The CRISPRi-dCas9 system utilizes a doxycycline-inducible deactivated Cas9 protein
fused to a KRAB (Krüppel-associated box) repression domain, targeting the RUNX1 gene and,
upon addition of doxycycline, prevents transcription of nascent RUNX1 mRNA (40) (Figure 6). In
the inducible CRISPRi system the target is not cleaved or excised, rather it is silenced and
repressed when doxycycline is present. This is because the Cas9, which holds helicase and
nuclease activity, has been deactivated (dCas9), resulting in a physical steric block that halts
transcription elongation by RNA polymerase (41).
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Image Source: Qi Lab, UCSF

Figure 6: The Inducible CRISPRi-dCas9 System Halts Transcription Elongation by Interfering with
RNA Polymerase. Upon dCas9 induction via doxycycline, dCas9 identifies a PAM sequence along
with a gene target using a specific sgRNA sequence. Once bound, dCas9-KRAB block transcription
of the target gene, generating a depletion of the target gene.
This differs from the original CRISPR system developed in 2012, which uses active RNAguided nucleases to recognize, cleave and degrade any foreign genetic elements (40). The
complete system is composed of CRISPRi dCas9-KRAB with a highly specific single guide RNA
(sgRNA) for the target gene of interest. Additionally, the target locus must contain a specific
protospacer adjacent motif (PAM) sequence, which in this case is NGG, where N is any
nucleotide (40). The ability for inducible CRISPRi to be highly programmable for the target gene
as well as completely reversible lends it to be one of the most useful tools in depletion and lossof-function studies.
Guide RNAs were chosen to target between 300 base pairs upstream and 100 bases
downstream of the RUNX1 transcription start site using the online tool Benchling CRISPR
design. Three guides, each of 20 base pairs, were designed for each RUNX1 promoter of
interest, denoted P1 and P2 (Table 1). All plasmids contained the same overhangs following
digestion and were used for cloning into lentiCRISPRv2 (or lentiCRISPRv1). The overhangs were
designed as shown below.
16

5’ – CACCGNNNNNNNNNNNNNNNNNNN – 3’
3’ – CNNNNNNNNNNNNNNNNNNNCAAA – 5’

Table 1: Design of Six CRISPRi Constructs Targeting Promoter 1 (P1) and Promoter 2 (P2) of
hRUNX1. Benchling CRISPR Design was utilized to target the RUNX1 transcription start site and
the automated DNA sequencing of the guides was performed in the University of Vermont
Cancer Center Advanced Genome Technologies Core.
Standard de-salted oligos were ordered from Invitrogen and resuspended to 100µM in
sterile water. Oligos were stored at -20°C. For each construct, each oligo pair was
phosphorylated and annealed. 1µl of 100µM oligo 1 was combined with 1µl of 100µM oligo 2,
1µl 10X T4 Ligation Buffer, 0.5µl T4 PNK (NEB M0201S), and 6.5µl ddH2O. The oligos were
annealed in a thermocycler at 37°C for 30 minutes followed by 5 minutes at 95°C and
subsequently ramped down to 25°C at 0.1°C/sec. The annealed oligos were pooled and diluted
1:250.
The digestion-ligation reaction was set-up by combining a variable volume of lentiguidepuro or other backbone vector (100ng), 2 µl of diluted phosphorylated and annealed oligo
duplex, 2 µl 10x FastDigest Buffer, 1 µl 10mM DTT, 1 µl 10 mM ATP, 1 µl FastDigest Esp3I
(Thermo Fisher), 0.5 µl T7 DNA ligase, and a variable volume of ddH2O for a combined total of
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20µl. A negative control digest using H2O was also established for the reaction. The ligation
reaction was incubated in a thermocycler for 5 minutes at 37°C followed by 5 minutes at 23°C,
and these two steps were repeated through six total cycles and held at 4°C. The exonuclease
treatment reaction consisted of 11µl of the ligation reaction, 1.5µl 10X PLasmidSafe Buffer,
1.5µl 10 mM ATP, and 1µl PlasmidSafe DNase and was incubated at 37°C for 30 minutes.
Plasmid (2µl) was transformed into 50µl of Stbl3 cells (Thermo Sci NC9046399) following
mix-and-go protocol. The cell suspension (50µl) was plated on plates containing ampicillin. The
following day, individual, homogenous bacteria cultures were selected using a sterile pipette.
shRNA-mediated Knockdown
Since the conception of early RNAi methods, such as small interfering RNA (siRNA),
methods have evolved to use shRNA. shRNA constructs are capable of DNA integration and are
therefore more stable and suitable for gene knockdown than siRNA (38). In shRNA, target
constructs are infected into the cell using virally produced vectors or are transfected as plasmid
vectors into the cell. The shRNAs consist of 19-22bp sequences linked by a short loop of
nucleotides akin to that of the hairpin structure found in naturally occurring microRNA. After
transcription of the newly integrated shRNA, the shRNA sequence is exported to the cytosol
where it is bound by the Dicer enzyme. Dicer then processes the shRNA into siRNA duplexes 2123 nucleotides long having 2-nucleotide-long 3’-overhangs on each strand, which subsequently
bind the target mRNA for incorporation into the RISC complex or bind to physically prevent
translation from occurring. RISC then unwinds the double-stranded siRNA and selects the
antisense (guide) strand that is complementary to the knockdown target. Finally, RISC and the
catalytically active subunit Argonaute protein family member (Ago) carry out the slicing function
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by cleaving the RNA transcript that is paired to the guide strand. This cleaving action therefore
prevents the expression of the gene product (Figure 7) (38, 42).
Recent studies achieving gene knockdown in mammalian cells have employed shRNA over
siRNA for a few reasons (39, 43, 44). One major concern with siRNA is off-target effects due to
the high concentration of siRNA in the cytoplasm. Though improved, this remains a concern for
shRNA (38). Another major concern for siRNA is that as the cells divide, the siRNA concentration
can become diluted, which can pose a significant issue with rapidly dividing cancer cells such as
MCF10AT1. shRNA is preferred for this gene knockdown study because it can be used to create
a stable cell-line via drug selection such as puromycin and fluorescent markers such as GFP that
may be used for FACS (38).

Figure 7: shRNA-Mediated Gene Silencing. The
shRNA is exported to the cytosol where it is
processed into siRNA duplexes that target the gene
of interest for degradation via RISC (7).
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Plasmid Isolation
Plasmid DNA was isolated using Zymo Research ZymoPURE Plasmid Midiprep Kit
(D4200). This kit utilizes a modified alkaline lysis method of plasmid purification and ensures
the plasmid is free of endotoxins, salts, proteins and RNA. Therefore, the prepared plasmids are
suitable for transfection, transformation, PCR amplification and DNA sequencing. The kit was
used according to manufacturer’s instructions using the centrifugation method. The nucleic acid
concentrations of each plasmid were analyzed using the ThermoFisher NanoDrop 2000 UV-Vis
spectrophotometer.
Virus Production
HEK293T cells were maintained in Dulbecco’s Modified Eagle Medium (Gibco, 11965)
supplemented with 10% fetal bovine serum (Valley Biomedical, BS3033). HEK293T cells were
split and plated at 1.3×105 cells/cm2. The following day, packaging plasmids and dCas9 or
sgRNA-coding plasmids were transfected using Lipofectamine 2000 transfection reagent
(Invitrogen, 11668500) into HEK293T cells in Opti-MEM (Gibco, 31985) according to the
manufacturer’s instructions. Virus was harvested 48 hours after transfection. Plasmids
containing either CRISPRi guide RNA or shRNA-RUNX1 were then transduced into 10A or AT1
cells. For inducible CRISPRi, dCas9 expression was induced by the addition of the antibiotic
doxycycline. Fresh doxycycline was added to fresh media at the concentration of 2µM every 24
hours to maintain dCas9 expression and therefore maintain the inhibition of RUNX1 by CRISPR.
shRNA Knockdown: Infection
Lentivirus-based RNAi transfer plasmids with pGIPZ shRUNX1 (clone V2LHS_150257 and
V3LHS_367631, GE Dharmacon) and pGIPZ non- silencing (Cat No. RHS4346, GE Dharmacon)

20

were purchased from Thermo Scientific. To generate lentivirus vectors, 293T cells in 10 cm
culture dishes were co- transfected with 10 μg of pGIPZ shRUNX1 or pGIPZ non- silencing, with
5 μg of psPAX2, and 5 μg of pMD2.G using lipofectamine 2000 reagent (Life Technologies).
Viruses were harvested every 48 h post-transfection. After filtration through a 0.45 μm-poresize filter, viruses were concentrated by using LentiX concentrator (Clontech, Mountain View,
CA, USA).
Gene delivery by transfection and infection
For shRNA-mediated knockdown of RUNX1 expression, MCF10A or MCF10AT1 cells
were plated in six- well plates (1x105 cells per well) and infected 24 hours later with lentivirus
expressing shRUNX1 or non-silencing (NS) shRNA. Briefly, cells were treated with 0.5 ml of
lentivirus and 1.5 ml complete fresh DMEM-F12 per well with a final concentration of 4 μg/ml
polybrene. Plates were centrifuged upon addition of the virus at 1460 × g at 37°C for 30 min.
Infection efficiency was monitored by GFP co-expression at 2 days post infection. Cells were
selected with 2 μg/ml puromycin (Sigma Aldrich P7255- 100MG) for at least two additional
days. After removal of the floating cells, the remaining attached cells were passed, harvested
for protein or RNA, and analyzed.
Western Blot Analysis
I.

Sample Harvest and Preparation
The cell culture of interest for protein analysis was harvested and lysed using 100-400µl
of ice-cold 1X RIPA per 10cm dish (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b–
glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) supplemented with complete, EDTA-free
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protease inhibitors (Roche Diagnostics) and the proteasome inhibitor MG132 (EMD Millipore
San Diego, CA, USA). Using a cell scraper, the cells were scraped and transferred to a
microcentrifuge tube and snap frozen in liquid nitrogen. The samples were kept at -80°C until
ready for analysis.
Each sample was then sonicated at an amplitude of 30 (Q700 Sonicator System, QSonica
Sonicators, Newtown, CT). Samples were subjected to a cycle of 10 seconds of sonication
followed by 30 seconds of rest on ice slurry, for a total of seven cycles (QSonica Microtip #4418,
1/8” Diameter). Samples were then centrifuged for 20 minutes at 15,000 RPM. 6µl of
supernatant was removed and diluted 10-fold in 1X RIPA for use in the BCA assay (see below).
The remainder of the supernatants were diluted in 5X loading dye and boiled for 5 minutes,
placed on ice for 1 minute, and stored at -80°C.
II.

Bicinchoninic Acid Assay (BCA Assay): Protein Quantification and Internal Controls
The Thermo Scientific Pierce BCA Protein Assay was utilized as a method to accurately
quantify the total amount of protein present in a sample. Protein standards using bovine serum
albumin (BSA) are prepared in order to quantify the sample protein concentrations based on
the absorbance at 562nm.
In a 96-well plate, BSA standards diluted in 1X RIPA with concentrations of 0.5µg/ml,
0.25µg/ml, 0.125µg/ml, 0.0625µg/ml, and 0.03125µg/ml were prepared. One blank consisting
of 1X RIPA was also prepared. Enough BCA working reagent was prepared in order for each
sample, measured in duplicate, and each standard to have 200µl. 50 parts of BCA reagent A was
mixed with 1 part of BCA reagent B. 200µl of working reagent was added to each well to be
measured. 25µl of each sample to be measured, including the standards, was loaded into an
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individual well and mixed thoroughly by pipetting (1:8 to the working reagent). The plate was
incubated for 30 minutes at 37°C. The plate was read using a plate reader at 562nm.
To quantify the protein concentration of each sample, a standard curve of known BSA
concentration vs. absorbance at 562 nm was generated. A computer-generated linear trend line
was added, displaying the slope and y-intercept values. The unknown samples were adjusted
for the value of the blank’s absorbance and averaged for each replicate. Using the linear trend
line, each unknown’s absorbance value was solved for x, the protein concentration. The 10-fold
dilution was accounted for, and the resulting value was multiplied by 1/40 to yield the
appropriate loading volume for 40µg of protein for the western blot.
III.

Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) & Protein
Transfer
The cell lysate samples were separated in an 8.5% acrylamide gel using polyacrylamide
gel electrophoresis and subsequently subjected to immunoblotting. The completed gels were
transferred to PVDF membranes (EMD Millipore) using an overnight wet transfer apparatus
(Bio-Rad Laboratories, Hercules, CA, USA). The membranes were blocked using 5% bovine
serum albumin (BSA) or 5% milk + 0.02% sodium azide (Sigma-Aldrich) and incubated overnight
at 4°C with the primary antibody. The Clarity Western ECL Substrates (Bio-Rad Laboratories)
were used 1:1 for immunodetection of HRP and imaged on a Chemidoc XRS+ imaging system
(Bio-Rad Laboratories). A full summary of antibodies used as well as their dilutions can be found
in table 2. To determine the relative expression of the target protein relative to the control
protein b-actin, FIJI (ImageJ) software was used to perform densitometry analyses. The FIJI
software determined density peaks for each protein band and calculated the area under each
peak. The peak values for each b-Actin band were then used with the peak values for the target
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protein bands to calculate a ratio that represented the change in expression of the protein of
interest relative to b-Actin. This method allowed for the selection of only the target protein
bands, however it did not allow for the standardization of background signaling that may have
occurred proximal to each band.
Target
RUNX1

Primary/Secondary
Primary

Species
Rabbit

Catalog No.
4336S

RUNX1

Secondary

Goat Anti-Rabbit HRP

3140

PIK3CA

Primary

Rabbit

4249

PIK3CA

Secondary

Goat Anti-Rabbit HRP

3140

PIK3R1

Primary

Rabbit

4257

PIK3R1

Secondary

Goat Anti-Rabbit HRP

3140

HA TAG dCAS9

Primary

Rabbit

3724

HA TAG dCAS9

Secondary

Goat Anti-Rabbit HRP

3140

!-Actin

Primary

Mouse

3700S

!-Actin

Secondary

Goat Anti-Mouse HRP

31430

Company
Cell Signaling
ThermoFisher Scientific
(Invitrogen)
Cell Signaling
ThermoFisher Scientific
(Invitrogen)
Cell Signaling
ThermoFisher Scientific
(Invitrogen)
Cell Signaling
ThermoFisher Scientific
(Invitrogen)
Cell Signaling
ThermoFisher Scientific
(Invitrogen)

Lot No.
4

Dilution Factor
1:1000

SA245916

1:3000

9

1:1000

SA245916

1:3000

6

1:1000

SA245916

1:3000

8

1:1000

SA245916

1:3000

10

1:5000

SD251027

1:5000

Table 2: Summary of antibodies and dilution factors used for western blot protocols.
shRNA Controls: Reporter Gene GFP Sorting and Puromycin Selection
To maintain an efficient and high-quality RUNX1 knockdown, the infected cells were
sorted via FACS based on relative expression of the pGIPZ reporter gene TurboGFP. The cells
were collected and resuspended in sterile PBS with 5% horse serum and DAPI (1:5000) and
subsequently sorted and plated. GFP efficiency and cell vitality was checked 24 hours later
(Figure 8). To further maintain RUNX1 knockdown, the sorted cells underwent a one-week
period of puromycin selection. Normal media was replaced with media containing 2µg/mL
puromycin. Cells expression the GIPZ plasmid will express both the shRNA as well as resistance
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to the antibiotic puromycin. The media was replaced every 24 hours to remove any floating and
dead cells and to replace with fresh media.
8A

8B

8C

Figure 8: GFP Expression in MCF10A shRNA-Mediated Knockdown. Expression of the pGIPZ
reporter gene GFP was analyzed using fluorescence microscopy to determine preliminary
RUNX1 knockdown efficiency. Non-silencing shRNA (A), shRUNX1 C1 (B), and shRUNX1 C4 (C).
Quantitative PCR (qPCR)
RNA was harvested from cells and isolated with Trizol (Life Technologies). The samples
were cleaned by DNase I digestion (Zymo Research, Irvine, CA, USA). RNA was reverse
transcribed using SuperScript IV and random hexamers (Life Technologies). The cDNA was
further cleaned with RNA removal via E. coli RNase H treatment (Life technologies). cDNA was
then subjected to quantitative PCR using SYBR Green technology (Applied Biosystems, Foster
City, CA, USA). The genes selected for qPCR analysis for this project were chosen based on
unpublished ChIP-Sequencing data (Andrew Fritz) that first identified where in the genome
RUNX1 binds. Additionally, unpublished RNA-sequencing data (Andrew Fritz) was used to
determine the change in expression of genes upon RUNX1 depletion. This information,
combined with genes known to drive BrCa (1), identified BrCa driver genes that may be under
RUNX1 regulatory control due to proximal binding to the gene transcription start site and due
to change in expression upon loss of RUNX1. A summary of primer sequence for these genes
can be found in table 3.
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Target
Forward Sequence
Reverse Sequence
SF3B1
GTGGGCCTCGATTCTACAGG
GATGTCACGTATCCAGCAAATCT
PIK3R1
ACCACTACCGGAATGAATCTCT
ACCACTACCGGAATGAATCTCT
KRAS
ACAGAGAGTGGAGGATGCTTT
TTTCACACAGCCAGGAGTCTT
FOXA1
GCAATACTCGCCTTACGGCT
TACACACCTTGGTAGTACGCC
PIK3CA
CCACGACCATCATCAGGTGAA
CCTCACGGAGGCATTCTAAAGT
TP53
CAGCACATGACGGAGGTTGT
TCATCCAAATACTCCACACGC
PTEN
TGGATTCGACTTAGACTTGACCT
GGTGGGTTATGGTCTTCAAAAGG
USP9X
TCGGAGGGAATGACAACCAG
GGAGTTGCCGGGGAATTTTCA
ATM
ATCTGCTGCCGTCAACTAGAA
GATCTCGAATCAGGCGCTTAAA
APC
AAAATGTCCCTCCGTTCTTATGG
CTGAAGTTGAGCGTAATACCAGT
PBRM1
AGGAGGAGACTTTCCAATCTTCC
CTTCGCTTTGGTGCCCTAATG
BUB1B
AAATGACCCTCTGGATGTTTGG
GCATAAACGCCCTAATTTAAGCC
GAPDH
TGTGGTCATGAGTCCTTCCA
ATGTTCGTCATGGGTGTGAA
RUNX1
AACCCTCAGCCTCAGAGTCA
CAATGGATCCCAGGTATTGG
CDH1
GGAAGTCAGTTCAGAGCATC
AGGCCTTTTGACTGTAATCACACC
ACTIN-B AGCACAGAGCCTCGCCCTT
CGGCGATATCATCATCCA
N-CADHERIN TGTTTGACTATGAAGGCAGTGG
TCAGTCATCACCTCCACCAT
VIMENTIN AGGAAATGGCTCGTCACCTTCGTGAATA GGAGTGTCGGTTGTTAAGAACTAGAGCT
Table 3: Summary of primer sequences used for quantitative PCR protocols.

Results
The central objective of this project was to first develop a RUNX1 loss of function model
in human BrCa cells (10A and AT1) using inducible CRISPRi and shRNA. Upon RUNX1 loss, this
study aimed to investigate how RUNX1 may be involved in the expression of predicted BrCa
driver genes based on preliminary RUNX1 ChIP-seq data, RNA-seq data, and the published
literature identifying BrCa driver genes (1). The long-term goal of this project is to therefore
identify BrCa driver genes putatively regulated by the tumor suppressor action of RUNX1.
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Doxycycline-Induced CRISPRi Knockdown of RUNX1
Previous work carried out by Alexandra Ojemann in the Stein/Lian laboratory
successfully isolated stable clonal populations of AT1 cells infected with the CRISPRi-dCas9KRAB system. Upon addition of varying concentrations of the antibiotic doxycycline to cells in
culture, dCas9 expression at the protein level was determined among four sets of clones
denoted as clones 1, 4, 5, and 6. Doxycycline induction was carried out for three days with
concentrations of 2µM, 5µM, and 10µM. In response to doxycycline, dCas9 was expressed at
the protein level, as determined by western blot analysis (Figure 9). The uninduced samples
(doxycycline = 0µM) were found to express no dCas9 (Figure 9).

Figure 9: Upon Dox-Induction, AT1 Cells Transfected with CRISPRi Plasmid pLV hU6-sgRNA
hUbC-dCas9-KRAB-T2a-GFP Expressed dCas9. dCas9 was expressed at the protein level in AT1
clones 1, 4, 5 and 6. Dox concentrations of 2µM, 5µM, and 10µM all demonstrated dCas9
expression. Standard western blot protocol was followed, and the antibody used was HA Tag
3724 Lot #8 Rabbit mAb (Cell Signaling).
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Relative to b-Actin expression, which was used as an internal control, dCas9 expression
among the AT1 clones did not directly correlate with doxycycline concentration. Higher
doxycycline concentration did not consistently result in a greater expression in dCas9 (Figure
10). In some AT1 clones, 2µM doxycycline was just as, or more, effective in inducing dCas9
expression than 10µM doxycycline. A complete summary of dCas9 expression at the protein
level upon the addition of doxycycline over the course of three days is included in Table 4.

Figure 10: Doxycycline Concentration and dCas9 Expression do not Directly Correlate. Varying
concentrations of doxycycline resulted in varying levels of dCas9 expression in AT1 clone 5 (7A) as well
as AT1 clone 4 (7B) at the protein level. Expression was determined via western blot analysis relative to
b-actin expression. One western blot was analyzed for each clone for each of three doxycycline
concentrations.
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Table 4: Doxycycline-Induced AT1 Clones Expressed dCas9 Protein. Upon addition of 2µM, 5µM, and
10µM doxycycline, AT1 clones 1,4,5 and 6 expressed dCas9 at the protein level. Doxycycline was
replenished every 24 hours for 72 hours total. Standard western blot protocol was followed, and 𝛃Actin served as a control. Using FIJI software, densitometry analysis was performed to yield the
expression of the dCas9 signal relative to b-Actin. HA Tag (dCas9) Primary Antibody: Rabbit mAb HA
Tag #3724 Lot 8 (Cell Signaling). b-Actin Primary Antibody: b-Actin Mouse mAb #3700S Lot 10 (Cell
Signaling)

29

Further AT1 clonal analysis was carried out to determine RUNX1 protein expression in
each of the four clones expressing dCas9 upon dox-induction. The first round of CRISPRimediated RUNX1 knockdown demonstrated a clear need for CRISPRi optimizations. Among AT1
clonal populations expressing the dCas9 plasmid, RUNX1 expression at the protein level varied
drastically between doxycycline concentrations and between consecutive days after infection
with the sgRNA CRISPRi guides targeting RUNX1 (Figure 11). A consistent knockdown trend was
not seen throughout the three days of doxycycline induction in any of the clones or at any
specific doxycycline concentration (Figure 12).

Figure 11: Upon Dox-Induction, AT1 Cells Infected with CRISPRi Plasmid pLV hU6-sgRNA hUbCdCas9-KRAB-T2a-GFP Expressed Variable Levels of RUNX1. AT1 clones 4 and 5 expressed
varying levels of RUNX1 at the protein level upon three days of doxycycline induction of varying
concentrations. Standard western blot protocol was followed. The RUNX1 antibody used was
AML1 Rabbit mAb #4336S Lot 4 (Cell Signaling). b-Actin served as a control, mouse mAb #3700S
Lot 10 (Cell Signaling).
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Figure 12: Upon Dox-Induction, AT1 Cells Infected with CRISPRi Expressed Variable Levels of RUNX1.
AT1 clones 4 (10A) and 5 (10B) expressed varying levels of Runx1 at the protein level upon three days
of doxycycline induction of concentrations 2µM, 5µM, and 10µM. Standard western blot protocol was
followed and the RUNX1 antibody used was AML1 Rabbit mAb #4336S Lot 4 (Cell Signaling). b-Actin
served as a control, mouse mAb #3700S Lot 10 (Cell Signaling).
Based on the variability of RUNX1 knockdown, the CRISPRi-dCas9 system was optimized
at the level of the virus production and the subsequent infection of the AT1 cells. We
hypothesized that increasing the quantity of virus would result in a more efficient and
consistent gene knockdown.
Increasing the Virus Titer of CRISPRi Targeting RUNX1 Yielded Greater Knockdown Efficiency
In order to gain a more significant and consistent knockdown of RUNX1 upon the
addition of doxycycline, the virus titer containing the sgRNA targeting RUNX1 was increased
five-fold. We hypothesized that a higher virus titer would result in a better knockdown of
RUNX1, as the infection efficiency would likely increase. Based on previous clonal protein
expression of RUNX1, clone 4 was selected to test the high virus titer CRISPRi knockdown. In
previous experiments, AT1 clone 4 was the only clone that displayed a consistent downward
trend of RUNX1 expression as the time progressed (Figure 12). Therefore, clone 4 was theorized
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to best show RUNX1 depletion upon infection with a five-fold increase in virus. After infection
of the sgRNA RUNX1 guides and upon addition of 2µM doxycycline every 24 hours for three
days, AT1 clone 4 displayed an appreciable net loss of RUNX1 at the protein level (Figure 13).
Samples were run in duplicate, generating a standard error of the mean. Replicate A
demonstrated a consistent and significant depletion in RUNX1 as time progressed, while
Replicate B showed RUNX1 depletion on days one and three with an increase in RUNX1
expression on day two, relative to b-actin (Figure 14). However, this is also true for the noninduced control of 0µM doxycycline (Figure 14). In both control replicates, RUNX1 expression
increased on day two and decreased again on day three (Figure 13, Figure 14). A potential
consideration for this result is that RUNX1 may exert a compensatory mechanism to combat the
repressive effects on the inducible CRISPRi dCas9-KRAB system to therefore maintain adequate
expression of RUNX1 in the cells, though additional biological replicates must be carried out to
fully investigate this finding.

Figure 13: Doxycycline-Induced RUNX1 CRISPRi Knockdown in MCF10AT1 Clone 4 cells. RUNX1
expression was analyzed via Western Blot analysis. Two replicates of AT1 cells were carried out
and 2µM Doxycycline was added every 24 hours for a 72-hour period. Samples were harvested
every 24 hours using 1X RIPA and standard RUNX1 Western Blot protocol was followed. RUNX1
antibody used: AML1 Rabbit mAb #4336S Lot 4 (Cell Signaling). b-Actin served as a control mouse
mAb #3700S Lot 10 (Cell Signaling).
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Figure 14: Doxycycline-Induced RUNX1 CRISPRi Knockdown in MCF10AT1 Clone 4 cells (Viral
Construct 5). RUNX1 protein expression was analyzed via Western Blot and quantified in
relation to b-actin expression. Two replicates of AT1 cells were performed and 2µM
Doxycycline was added every 24 hours for a 72-hour period. Samples were harvested every 24
hours using 1X RIPA and standard RUNX1 Western Blot protocol was followed. Using FIJI
software, densitometry analysis was performed to yield the expression of the RUNX1 signal
relative to b-Actin. Error bars represent the standard error of the mean (SEM).

In four AT1 clonal populations previously developed by Alexander Ojemann of the
Stein/Lian group, dCas9 was expressed upon doxycycline-induction as early as 24 hours and at a
concentration as low as 2µM (Table 4). dCas9 expression therefore confirmed successful
transfection of the dCas9-KRAB plasmid and allowed for dox-induced RUNX1 gene silencing
studies to be performed. Initial doxycycline induction in AT1 clone 4 did not yield significant
knockdown of RUNX1, as RUNX1 expression was highly variable between 24-hour harvest
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points and between doxycycline concentrations used for induction (Figure 14). To optimize the
inducible CRISPRi system, five times the quantity of virus carrying the sgRNA guides targeting
RUNX1 was generated in HEK293T cells. Upon infection, RUNX1 knockdown improved
compared to previous studies, but did not show consistency or validity compared to the
uninduced control samples (Figure 14). For these reasons, and due to time constraints, the
CRISPRi-mediated knockdown system was no longer pursued, and we began developing a
RUNX1 knockdown system using shRNA in order to perform downstream genomic analyses in
cells depleted of the RUNX1 transcription factor.
shRNA-Mediated Knockdown of Runx1
A second gene knockdown tool, shRNA, was utilized in the 10A series in order to gain a
more complete and consistent depletion of RUNX1. The shRNA system has proven effective and

Figure 15: Protein expression profile of MCF10A and MCF10AT1 upon shRNA knockdown
targeting RUNX1. GFP+ 10A and AT1 cells were selected for via FACS and standard western
blot protocol for RUNX1 was followed. NS: shRNA non-silencing construct. shRUNX1-1:
shRNA RUNX1 knockdown construct. RUNX1 AML1 Rabbit mAb #4336S Lot 4 (Cell
Signaling) 𝛃-Actin served as a control mouse mAb #3700S Lot 10 (Cell Signaling).
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successful in our lab and was therefore the method of choice to mediate RUNX1 depletion in a
timely manner (3).
Knockdown of RUNX1 in both 10A and AT1 cells by shRNA proved effective at the
protein level. Western blot analysis determined that RUNX1 was decreased over 70% relative to
the non-silencing shRNA in both the 10A and AT1 cells (Figure 15, Figure 16).
Short hairpin RNA knockdown also proved efficient at the RNA level. qPCR was carried
out for cDNA of shRunx1 AT1 cells to determine the RNA expression of RUNX1 as well as Ecadherin (CDH1) following depletion of RUNX1. Expression change relative to the housekeeping
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Figure 16: RUNX1 protein expression change upon shRUNX1 knockdown in 10A and
AT1 cells. Relative to 𝛃-Actin, RUNX1 was depleted by 72% in 10A cells (n=1) and 77%
in MCF10AT1 cells (n=1) using shRUNX1-1. NS: shRNA non-silencing construct.
shRUNX1-1: shRNA RUNX1 knockdown construct. Using FIJI software, densitometry
analysis was performed to yield the expression of the RUNX1 signal relative to b-Actin.
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gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as well as the non-silencing (NS)
construct yielded DDCT values for gene expression of RUNX1 and CDH1. Fold expression change
was calculated by raising (-DDCT) to the power of 2. In AT1 cells, RUNX1 depletion resulted in a
loss of the epithelial marker CDH1, lending further support to previous findings that RUNX1 loss
advances the mesenchymal phenotype and EMT (Figure 17).

Figure 17: shRNA-Mediated Knockdown of RUNX1 Decreases CDH1 Expression at the RNA
Level in AT1 Cells. Upon shRNA-mediated knockdown of RUNX1, qPCR analysis determined
that CDH1 decreased at the mRNA level. Gene expression levels are relative to GAPDH as
well as the non-silencing (NS) shRNA construct. Error bars represent SEM. qPCR was run in
duplicate for two biological replicates.
To investigate the role of RUNX1 as a tumor suppressor, potential BrCa driver genes
were identified using unpublished ChIP-seq and RNA-seq data from the Stein/Lian lab (Andrew
Fritz). The ChIP-seq data identified where in the genome RUNX1 is normally bound, while the
RNA-seq data identified the change in expression of genes upon RUNX1 depletion. Together
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with this, as well as data published from Serena Nik-Zainal and colleagues (1), we identified top
BrCa driver genes with transcription start sites that RUNX1 proximally binds to and that RUNX1
may exert regulatory control over (Table 5). This yielded a list of 11 BrCa driver genes that
change in expression upon RUNX1 depletion and contain transcription start sites at which
RUNX1 binds.
Table 5: Based on whole-genome
analysis of 1,332 breast cancers,
driver genes based on mutation
frequency were found (1).
Subsequent analysis based on
driver gene rating, distance from
gene TSS to RUNX1 binding, and
change in expression upon
RUNX1 depletion generated a
subset of BrCa driver genes that
may be under the control of
RUNX1.

After successful depletion of RUNX1 in 10A and AT1 cells using shRNA, the regulatory
action of RUNX1 on these specific BrCa driver genes was investigated. Phosphatidylinositol-4,5Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) and Phosphoinositide-3-Kinase
Regulatory Subunit 1 (PIK3R1) are two kinase protein components that are part of the same
kinase protein complex and that were determined to be commonly mutated in BrCa and
therefore identified as BrCa driver genes (1). Upon RUNX1 depletion, the RNA and protein
expression profiles of these specific kinases were analyzed to determine if PIK3CA and PIK3R1
are under the regulatory control of RUNX1. qPCR data revealed that RUNX1 knockdown
resulted in an increase in both PIK3CA and PIK3R1 RNA expression compared to non-silencing
(Figure 18). At the protein level, RUNX1 depletion in AT1 cells resulted in an increase in PIK3CA
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(Figure 19). Conversely, RUNX1 depletion did not significantly alter the protein expression of
PIK3R1 (data not shown).

Figure 18: Expression of PIK3CA/R1 Increased upon RUNX1 Knockdown in 10A Cells. qPCR determined
that upon shRNA knockdown of RUNX1 in 10A cells there was an increase in PIK3CA and PIK3R1 mRNA
expression, suggesting a role for RUNX1 in regulating PI3K kinase functions in BrCa. Error bars represent
the SEM. NS: shRNA non-silencing construct. shRUNX1-1: shRNA RUNX1 knockdown construct 1.
shRUNX1-2: shRNA RUNX1 knockdown construct 2.

Figure 19: Expression of PIK3CA protein increased upon
RUNX1 knockdown in AT1 cells. Western blot analysis
determined that upon shRNA knockdown of RUNX1 in AT1
cells there was an increase in PIK3CA protein expression,
suggesting RUNX1 exerts regulatory action on PIK3CA’s
function in BrCa. Standard western blot protocol was
followed, and b-Actin served as a control. NS: shRNA nonsilencing construct. shRUNX1-1: shRNA RUNX1 knockdown
construct. Primary antibodies used: RUNX1 AML1 Rabbit
mAb #4336S Lot 4 (Cell Signaling); PIK3CA Rabbit mAb #4249
(Cell Signaling); b-Actin Mouse mAb #3700S Lot 10 (Cell
Signaling).
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The shRNA knockdown system targeting RUNX1 proved effective in depleting RUNX1 at
the transcriptomic level. In 10A and AT1 cell models, representing both normal-like and tumorlike cells, RUNX1 was decreased by approximately 70% (Figure 16). This level of RUNX1
depletion resulted in a decrease in RNA expression of the epithelial marker E-cadherin (Figure
17) and an increase in the RNA expression of PIK3R1 (Figure 18) and an increase in both the
RNA and protein expression of PIK3CA (Figure 18, Figure 19). These preliminary results suggest
that RUNX1 may exert regulatory control over the PI3K signaling pathway in a repressive
manner, since upon depletion the expression of PI3K kinase proteins increased in both 10A and
AT1 cells. These findings were found in duplicate (n=2) for RNA expression of PIK3CA and
PIK3R1 in 10A cells, while the findings for PIK3CA protein expression in AT1 cells were found in
one biological replicate of shRNA-mediated RUNX1 depletion.
Discussion & Future Directions
Loss-of-function studies are instrumental in advancing our knowledge of how a gene
exerts regulatory control in the cell. There is evidence that RUNX1 may act as a tumor
suppressor gene through its action as a transcription factor and master regulator of various
cellular pathways that are critical to cellular development, survival, growth and proliferation (3,
4, 45). In this project, two systems were utilized to generate a loss of RUNX1 function in the
MCF10 BrCa cell series; inducible CRISPRi-dCas9-KRAB and shRNA.
Inducible CRISPRi is one of the most well-known genome editing tools in scientific
research today. The precision, stability and reproducibility of the system make it a premier
option for use in gene activation or inhibition studies. In this study, inducible CRISPRi
optimizations and successive trials did not produce a RUNX1 knockdown sufficient for
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downstream analyses. This, in concert with time constraints, led us to utilize the shRNA system
for knockdown of RUNX1. However, it may be the case that the inducible CRISPRi system has its
own limitations depending on the target gene. It was demonstrated here that across multiple
clonal populations, cells expressed adequate dCas9 protein for multiple days across multiple
concentrations of doxycycline (Table 4). The expression of dCas9 is a key indicator that the
inducible system has been acquired by the cell and is a good indication of possible gene
knockdown. However, a serious concern for inducible CRISPRi that targets RUNX1 is the fact
that the RUNX1 gene is regulated by two different promoters known as P1 and P2, each of
which contributes to the overall expression of RUNX1. Additionally, the promoters P1 and P2
function differently in different cell types. We designed guides for both P1 and P2, three guides
per promoter for a total of six guides (Table 1). Therefore, in order for the CRISPRi system to be
effective in generating an appreciable knockdown of at least 80%, gene silencing at both
promoters P1 and P2 must be achieved. This requirement was likely a limitation for the CRISPRi
system, as failure of gene knockdown at just one promoter would allow for RUNX1 expression.
This addresses a major hurdle facing loss-of-function studies, as it can be much more difficult to
generate a complete silencing of a gene compared to hyper activating or overexpressing a gene.
A theoretical limitation of this study may lie within the fact that RUNX1 is a true master
regulator in the breast epithelial cells. Even as the CRISPRi experiment was optimized, either by
clonal selection for high dCas9 expression, or by increasing the virus titer, adequate knockdown
was not consistently achieved. It may be possible that RUNX1 holds a compensatory or reserve
mechanism to ensure its expression, as it is vital to many processes within the cell including
signaling pathways, growth and proliferation, cell survival and DNA damage response (4).
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Similarly, this is plausible since CRISPRi utilizes a deactivated Cas9 in place of Cas9 and does not
exert nuclease activity on the target gene. It is therefore a matter of steric interference via the
KRAB repression domain that blocks transcription, not permanent gene excision as seen in the
classical CRISPR-Cas9 model. This system is therefore developed to create a non-permanent
loss of RUNX1. For that reason, RUNX1 may be able to exert a compensatory mechanism that
results in decreased efficiency for dCas9-KRAB binding and transcriptional silencing in the cell.
Conversely, perhaps the CRISPRi system is ineffective in targeting RUNX1 at the genomic
level because doing so activates apoptotic events in the cell. Apoptotic studies were not
performed in this project, though it may be important to determine if RUNX1 repression at the
genomic level in BrCa is too catastrophic for the cell, leading to apoptotic events for the
population of cells that the CRISPRi system was successful. These events would therefore only
leave behind the population of cells for which RUNX1 expression was not repressed, as seen in
this project.
Other CRISPRi limitations may simply lie within the optimization of the experimental set
up. We found that increasing the virus titer and raw production of the virus five-fold yielded a
more efficient knockdown (Figure 14). Further optimization with an even higher virus titer
could therefore be conducted to generate sufficient knockdown of RUNX1. Additionally, this
project only utilized a total of six CRISPRi guides (Table 1). Three guides were designed to target
RUNX1 promoter 1 and three guides were designed to target RUNX1 promoter 2. The online
CRISPR design tool, Benchling, was utilized in the design of these guides and therefore they
should contain the necessary parameters for effective knockdown. However, as these guides
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did not prove very effective, a new set of guides may need to be designed for successful
knockdown. Due to time constraints for this project, we did not pursue generating new guides.
shRNA-mediated depletion of RUNX1 proved to be an effective method of knocking
down RUNX1 expression at the protein level as well as at the RNA level (Figure 15, Figure 16).
shRNA targeting RUNX1 was previously performed in our laboratory (3) and was therefore a
dependable choice for a knockdown system when facing time constraints. At the protein level,
RUNX1 was knocked down approximately 75% in both the 10A and AT1 cell line. qPCR of two
replicates in AT1 cells also identified a significant reduction in expression of RUNX1 at the RNA
level upon shRNA knockdown (Figure 17). These results allowed for further analyses of the
tumor suppressor role of RUNX1 in BrCa.
Quantitative PCR first validated the role of RUNX1 in maintaining the epithelial
phenotype by preventing EMT as first demonstrated by Hong and colleagues (3). We found that
in AT1 cells across two replicate samples, a reduction of RUNX1 RNA expression resulted in a
dramatic decrease of the RNA expression of the epithelial marker E-cadherin, as compared to
the non-silencing shRNA control (Figure 17). This lends evidence in support of the tumor
suppressor role of RUNX1 in BrCa, as maintenance of the epithelial phenotype and prevention
of EMT are essential in preventing cancer progression and aggression.
Most notably, we determined that upon depletion of RUNX1, there was a clear increase
in PIK3CA and PIK3R1 expression at the RNA level in 10A cells (Figure 18). At the protein level,
an increase in PIK3CA expression was found upon RUNX1 depletion in AT1 cells (Figure 19).
PIK3CA and PIK3R1 are genes of the phosphatidylinositol-3-kinase (PI3K) pathway that are
commonly mutated in human cancers (27). PI3K signaling is a critical pathway involved in both
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normal and malignant cellular processes including cell growth, proliferation and apoptosis
(Figure 20) (46). Notably, the PIK3CA gene has been found to be mutated in more than onethird of breast cancers (27). Additionally, one study determined that 9% of the study’s cohort of
breast cancer patients harbored both PIK3CA and PIK3R1 mutations that resulted in
hyperactivity of the PI3K pathway and oncogenesis (47).
Using an unpublished ChIP-Seq data set that identified where the RUNX1 protein is
bound throughout the genome (Andrew Fritz), PIK3R1 was identified as a BrCa driver gene that
RUNX1 binds proximal to the transcription start site (Table 5). Similarly, PIK3CA was identified
as a BrCa driver gene that RUNX1 binds, though less proximal than the transcription start site of
PIK3R1. Unpublished RNA-seq data (Andrew Fritz) also determined that upon RUNX1 depletion,
PIK3CA and PIK3R1 are upregulated in expression (Table 5). RUNX1 regulatory control of PIK3CA
may therefore occur via distant enhancers or genomic lopping domains, while RUNX1 control of
the PIK3R1 gene may occur at the transcription start site. It was confirmed that upon RUNX1
knockdown in BrCa, there is a significant increase in expression of PIK3CA and PIK3R1 compared
to the non-silencing sample which expressed RUNX1 protein and RNA. Although PIK3CA and
PIK3R1 are among the most commonly mutated genes in breast cancer, it is the difference
between the non-silencing vector and the shRNA vector truly targeting RUNX1 that
demonstrates the regulatory control of RUNX1 on these important PI3K pathway oncogenic
genes. Since RUNX1 exerts regulatory control with a myriad of genes involved in growth and
development, the negative regulation of PIK3CA and PIK3R1 may therefore be direct or indirect.
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The PI3K pathway is vast, exerting control over and interacting with components
including AKT, mTOR, RAS, VEGF, and EGF, all of which have roles in cell growth, survival,
proliferation, morphology, apoptosis, migration and adhesion (Figure 20) (9, 48). For these
reasons, hyperactivation of PIK3CA and PIK3R1 upon loss of RUNX1 may be a critical part of
cancer progression toward metastasis and invasion, ultimately resulting in poor patient
prognosis. Moreover, the high frequency of PIK3CA mutations in BrCa has focused on PIK3CA
inhibition as a novel clinical target and potential drug scheme for BrCa treatment (49). RUNX1

Acquired from: Hennessy BT et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005.

Figure 20: Schematic of Signaling Through the Phosphatidylinositol-3-Kinase (PI3K)/AKT
Pathway. The PI3K/AKT and other interrelated pathways are essential in perceiving the
effects of external growth signals and associated membrane tyrosine kinases. AKT is
activated downstream of PI3K and effects a multitude of targets (9). EGFR, epidermal
growth factor receptor; AMPK, AMP-activated protein kinase; mTOR, mammalian target of
rapamycin; ERK, extracellular signal regulated kinase; FKHR, forkhead; GDP, guanosine
diphosphate; IRS, insulin receptor substrate; GSK3, glycogen synthase kinase 3; MAPK,
mitogen-activated protein kinase; NF-kB, nuclear factor-kB, PIP2, phosphatidylinositol-3,4diphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; PKC, protein kinase C.

44

inhibition may therefore not achieve PI3K inhibition, since RUNX1 may negatively regulate PI3K
proteins. Rather, RUNX1 activation could work to suppress the hyperactivity of the PI3K
pathway commonly seen in BrCa.
Cancer stem cells (CSCs) are another essential area of oncological research today. CSCs
are a unique subgroup of the cancer cell population able to propagate new tumors while
displaying the ability to self-renew. These traits contribute to the lethal nature of CSCs, as they
pose a significant threat when coupled with the canonical hallmarks of cancer (11). CSCs
are known to evade current cancer treatment options such as chemotherapy and radiation and
are therefore a crucial facilitator in patient relapses and overall aggression of the cancer. By
analyzing the downstream gene expression of those genes identified as BrCa drivers in
response to RUNX1 depletion and their role in CSC formation and/or maintenance, this project
can further examine the tumor suppressor role of RUNX1 in breast cancer and how RUNX1 may
work to halt the production of CSCs and the epithelial to mesenchymal transition. With novel
insight as to how RUNX1 functions in BrCa, we will be able to develop a safer, more targeted,
and more effective plan of action to eradicate one of the deadliest diseases that exists today.
In future studies, the role of RUNX1 in the BCSC population can be analyzed via
CD24/CD44 sorting of cells treated with shRUNX1 and shNon-Silencing. The CSC proportions of
the culture population can then be found using FACS, as CSCs are characteristically labeled as

CD24 /CD44+ with regard to cell-surface markers. RNA and protein expression profiles of the
predicted BrCa driver genes presented here may be carried out on the RUNX1 depleted BCSC
subpopulation. This, in addition to the qPCR data presented here, will develop a clearer picture
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of how RUNX1 functions in BrCa progression and aggression. Further studies will also require
optimization of inducible CRISPRi, a system designed to deplete RUNX1 upon the addition of
the antibiotic doxycycline through the activation of dCas9. Clonal selection and dCas9
expression upon dox-induction has been carried out, though more optimization is needed to
yield a knockout greater than 80% at both promoters of RUNX1. This inducible system will
provide a real-time snapshot of the effects of RUNX1 depletion, as it can be turned on and off
with the use of doxycycline.
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